> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# J&J Discontinues Dengue Virus Antiviral Development
- URL: https://www.fdaweb.com/j-j-discontinues-dengue-virus-antiviral-development/
- Published: 2024-10-04T12:00:00.000Z
- Updated: 2026-09-14T14:43:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157923

Johnson & Johnson is discontinuing a Phase 2 study (NCT05201794) evaluating mosnodenvir for preventing dengue virus in adults aged 18-65 years. The move to discontinue the study is part of the company’s “strategic reprioritization” of its communicable diseases research and development portfolio, J&J says, adding that no safety issues were identified. Efficacy data from the Phase 2 study will be available once the final data analyses are complete, it says.

Mosnodenvir was shown to be safe and well tolerated in earlier Phase 1 and Phase 2a clinical studies, J&J says. “Results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo,” it says.